- Germany-based research institute BioMed X is broadening an existing partnership with AbbVie (NYSE:ABBV) to focus on immunology and tissue engineering.
- The current arrangement has involved research into Alzheimer's disease.
- BioMed X is also launching a research institute in the US, based in New Haven, Conn.
- In October 2022, BioMed X signed a collaboration agreement with Sanofi (SNY) to develop an artificial intelligence platform to predict the efficacy of drugs in development to better inform which ones to advance.